⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008628 | 0.74 | — | — | |
| SCHEMBL190249 | 0.74 | — | — | |
| SCHEMBL29483856 | 0.72 | — | — | |
| SCHEMBL63023 | 0.72 | — | — | |
| SCHEMBL18171776 | 0.72 | GABRA1 (0.41) | — | |
| SCHEMBL383108 | 0.72 | — | — | |
| Fluoride SCHEMBL27460684 | 0.70 | — | — | |
| SCHEMBL61299 | 0.70 | — | — | |
| SCHEMBL3754047 | 0.69 | MEN1 (0.56) | — | |
| SCHEMBL558541 | 0.69 | MAPK9 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929675-B | Synthesis method of piperaquine Bai Xili | 苏州特瑞药业股份有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-113929675-A | Method for synthesizing piperazine cypress Xili | 苏州特瑞药业有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-9676731-B2 | Preparation of pyrimidine intermediates useful for the manufacture of macitentan | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-06-13 | — | — | US | claimed |
| US-20160318879-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-03 | — | — | US | claimed |
| US-20160052891-A1 | PREPARATION OF PYRIMIDINE INTERMEDIATES USEFUL FOR THE MANUFACTURE OF MACITENTAN | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-25 | — | — | US | claimed |
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727921-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4619397-A1 | SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| EP-1794120-A2 | PEPTIDASE INHIBITORS | Royalty, Susan Marie (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006012395-A2 | PEPTIDASE INHIBITORS | ROYALTY SUSAN MARIE (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |